Concepedia

Veerabhadran Baladandayuthapani

VB

83

Publications

4.8K

Citations

37

H-Index

2005

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

University of Michigan

Rice University

Texas A&M University

Baylor College of Medicine

Veerabhadran Baladandayuthapani is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cell biology, and systems biology.

ORCID

Top concepts

Publications per year

2005–2024

83

Publications

83

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Jason R. Westin, Fuliang Chu, Min Zhang et al. · The Lancet Oncology · 2013 · 528 citations · Full text

, , +10

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Nathan Fowler, R. Eric Davis, Seema Rawal et al. · The Lancet Oncology · 2014 · 258 citations · Full text

, , +5

Phase I Clinical Trial of Systemically Administered TUSC2(FUS1)-Nanoparticles Mediating Functional Gene Transfer in Humans

Charles Lu, David J. Stewart, J. Jack Lee et al. · PLoS ONE · 2012 · 181 citations · Full text

Ursolic Acid Inhibits Growth and Metastasis of Human Colorectal Cancer in an Orthotopic Nude Mouse Model by Targeting Multiple Cell Signaling Pathways: Chemosensitization with Capecitabine

Sahdeo Prasad, Vivek R. Yadav, Bokyung Sung et al. · Clinical Cancer Research · 2012 · 178 citations · Full text

Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma

Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones et al. · Blood · 2012 · 172 citations · Full text

Rows per page

1–5 of 83